Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278141 | 0.94 | S1PR1 (0.48) | S1PR1S1PR3SMN1; SMN2ALDH1A1CNR1 | |
| SCHEMBL12373690 | 0.92 | S1PR1 (0.41) | S1PR1S1PR3CNR1 | |
| SCHEMBL12373550 | 0.91 | S1PR1 (0.59) | S1PR1S1PR3SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL12373517 | 0.89 | S1PR1 (0.44) | S1PR1S1PR3ALDH1A1CNR1KMT2A | |
| SCHEMBL12373675 | 0.89 | S1PR1 (0.45) | S1PR1S1PR3SMN1; SMN2CNR1 | |
| SCHEMBL12373473 | 0.89 | S1PR1 (0.53) | S1PR1S1PR3ALDH1A1KMT2ACYP2D6 | |
| SCHEMBL12373849 | 0.88 | S1PR1 (0.47) | S1PR1S1PR3ALDH1A1CNR1KMT2A | |
| SCHEMBL12373619 | 0.88 | S1PR1 (0.48) | S1PR1S1PR3CNR1 | |
| SCHEMBL12373549 | 0.88 | S1PR1 (0.44) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12373635 | 0.87 | S1PR1 (0.43) | S1PR1S1PR3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994204-B2 | Binding inhibitor of sphingosine-1-phosphate | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182144-A1 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885S1PR3 2/4885SMN1; SMN2 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.